RCM
PCRX icon

Raleigh Capital Management’s Pacira BioSciences PCRX Stock Holding History

Raleigh Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-537
Closed -$10.1K – 900
2024
Q4 		$10.1K Hold
537
– – ﹤0.01% 605
2024
Q3 		$8.08K Hold
537
– – ﹤0.01% 630
2024
Q2 		$15.4K Buy
+537
New +$15.3K 0.01% 482

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Raleigh Capital Management's PCRX Position: Q1 2025 in Review

Raleigh Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 537 shares — an estimated $10.1K sold.

Raleigh Capital Management first reported a position in PCRX in Q2 2024 and held it in 3 quarters. The position peaked at $15.4K in Q2 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Raleigh Capital Management reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 537 Pacira BioSciences shares in Q1 2025, an estimated $10.1K.
  • Raleigh Capital Management first reported a position in Pacira BioSciences in Q2 2024 and held it in 3 quarters.
  • Raleigh Capital Management's Pacira BioSciences position peaked at $15.4K in Q2 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.